Natus Medical Incorporated (BABY) insider have most recently took part in a trading activity. On Jun 15, 2017 Hawkins James B, President and CEO bought 4,000 shares having total worth of $135,920 at the price of $33.98 per share, following the transaction a total of 578,023 shares owned by Hawkins James B. Before this latest buy, Hawkins James B purchased BABY at 4 other times during the past twelve months, for a total investment of $13.23M at an average of $36.45 per share.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 9 times by insiders. In 5 of these trades, the insider was a seller while an employee of the company was the buyer in 4 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Natus Medical Incorporated (BABY) traded down 1.27% on Jun 14, 2017, hitting $35. 243,315 shares of the company’s stock traded hands. Natus Medical Incorporated has a 52 week low of $29.68 and a 52 week high of $46.15. The company’s market cap is $1,300 million.
Natus Medical Incorporated (BABY) last announced its earnings results on Apr 26, 2017. The company reported 0.30 earnings per share (EPS) for the quarter, lower than the consensus estimate of 0.33 by $0.03. The company had revenue of $125 million for the quarter, compared to the consensus estimate of $123 million. During the same quarter in the previous year, the company posted 0.34 earnings per share. The company’s revenue for the quarter was up 43% on a year-over-year basis.
|earnings per share||0.30||0.51||0.39||0.39||0.34||0.51||0.39||0.34||0.31||0.40|
Natus Medical Incorporated, a Delaware corporation was incorporated in May 1987. The Company is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The company’s products are categorized into: Neurology and Newborn Care and Other. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intraoperative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care and other includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. It purchases materials and components from qualified suppliers that are subject to its quality specifications and inspections. It faces competition from other companies in all of its product lines. The Company’s competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018